Abstract: A composition and method for insect repellent is provided. The composition in one form has on a weight percentage basis 2-4% ?-pinene; 2-4% borneol; 8-10% geraniol; 28-35% linalool; 25-38% linalyl acetate; 1-4% methyl salicylate; 2-4% myrcene; 2-4% para-cymene; 4-8% phellandrene; 1-4% thymol; and 2-4% vanillin. The composition has insect repellent properties.
Type:
Grant
Filed:
February 14, 2022
Date of Patent:
May 21, 2024
Assignee:
Global Biolife Inc.
Inventors:
Daryl L. Thompson, Thomas A. Meyer, Nicholas A. Van Rees
Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Abstract: The invention generally relates to shape memory films that are tri-functionally crosslinked and that comprise multiple, non-terminal, phenylethynyl moieties. In addition, the present invention relates methods of fabricating such films. Due to the improved properties of such SMPs, the SMP designer can program in to the SMP thermomechanical property enhancements that make the SMP suitable, among other things, for advanced sensors, high temperature actuators, responder matrix materials and heat responsive packaging.
Type:
Grant
Filed:
July 21, 2022
Date of Patent:
May 7, 2024
Assignee:
United States of America as represented by the Secretary of the Air Force
Inventors:
Loon-Seng Tan, David H. Wang, Zhenning Yu
Abstract: The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.
Type:
Grant
Filed:
January 27, 2022
Date of Patent:
May 7, 2024
Assignees:
Neurolixis, The Regents of the University of California
Inventors:
Adrian Newman-Tancredi, Mark A. Varney, Khaleelurrahman Abdulrazak, Xin Tao
Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
April 23, 2024
Assignee:
PFIZER INC.
Inventors:
Ketan Satish Gajiwala, Chan Woo Huh, Mehran Jalaie, Ryan Lloyd Patman, Eugene Yuanjin Rui, Jianmin Sun, Martin James Wythes
Abstract: Provided herein are bifunctional compounds having the chemical structure I: PTM-L-CLM??(I): or pharmaceutically acceptable salts thereof, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF) and are useful in the treatment of a variety of Raf mediated conditions or diseases, such as cancer, specifically lung cancer, skin cancer, or colorectal cancer.
Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
Type:
Grant
Filed:
January 28, 2022
Date of Patent:
April 9, 2024
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
Type:
Grant
Filed:
February 27, 2019
Date of Patent:
April 2, 2024
Assignee:
MELINTA SUBSIDIARY CORP.
Inventors:
David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
Type:
Grant
Filed:
July 2, 2019
Date of Patent:
March 12, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz
Abstract: A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
Abstract: Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.
Type:
Grant
Filed:
April 21, 2020
Date of Patent:
January 30, 2024
Assignees:
CASE WESTERN RESERVE UNIVERSITY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Nicole F. Steinmetz, Stephen J. Lippard, Anna Czapar, Yaorong Zheng
Abstract: For the prevention of parasite infestation of animals, an isoxazoline can be administered by drinking water route. However the inventors have found that when the drinking water is sanitized, for instance by using hypochlorite, the isoxazoline becomes degraded. Surprisingly, the isoxazoline can be protected from degradation by the use of a vitamin E. A pharmaceutical composition can now be prepared containing a concentrated solution of the isoxazoline in a solvent and co-solvent, with vitamin E. The composition can be diluted in drinking water, even when sanitized, to prepare medicated drinking water for animals. This way an anti-parasitic treatment can be mass-administered, leading to a highly effective reduction of the parasite infestation of an animal, and its surroundings.
Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
January 23, 2024
Assignee:
Bristol-Myers Squibb Company
Inventors:
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, John L. Gilmore, Tasir Shamsul Haque, Trevor C. Sherwood, Brian K. Whiteley, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula, Pitani Veera Venkata Srinivas
Abstract: Methods of treating subjects having disorders associated with mutations in the FXN gene and/or having reduced expression of frataxin protein, e.g., Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases expression of frataxin protein as described herein, e.g., an inhibitor of a FXN Repressing Factor (FXN-RF).
Abstract: A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.